Everolimus in Heart Transplantation: An Update

@inproceedings{Hirt2013EverolimusIH,
  title={Everolimus in Heart Transplantation: An Update},
  author={Stephan W. Hirt and Christoph Bara and Markus J. Barten and Tobias Deuse and Andreas O. Doesch and Ingo Kaczmarek and Uwe Schulz and J{\"o}rg Stypmann and Assad Haneya and Hans Brendan Lehmkuhl},
  booktitle={Journal of transplantation},
  year={2013}
}
The evidence base relating to the use of everolimus in heart transplantation has expanded considerably in recent years, providing clinically relevant information regarding its use in clinical practice. Unless there are special considerations to take into account, all de novo heart transplant patients can be regarded as potential candidates for immunosuppression with everolimus and reduced-exposure calcineurin inhibitor therapy. Caution about the use of everolimus immediately after… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • 2016
View 1 Excerpt

De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation • 2015
View 1 Excerpt

Natural products as probes in pharmaceutical research

Journal of Industrial Microbiology & Biotechnology • 2015
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 76 references

Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • 2013

Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation • 2012

I

L. Potena, P. Prestinenzi
G. Bianchi et al., “Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHI- RAKISS randomized, prospective study,” Journal of Heart & Lung Transplantation, vol. 31, no. 6, pp. 565–570 • 2012
View 2 Excerpts

J

F. Gonzalez-Vilchez
A. Vazquez de Prada, L. Almenar et al., “Withdrawal of proliferation signal inhibitors due to adverse events in the maintenance phase of heart transplantation,” Journal of Heart & Lung Transplantation, vol. 31, no. 3, pp. 288– 295 • 2012

Withdrawal of proliferation signal inhibitors due to adverse events in the maintenance phase of heart transplantation.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation • 2012

81 Early vs delayed everolimusin de novo heart transplant recipients

M. Rinaldi, C. Maiello
Journal of Heart & Lung Transplantation • 2011

C

L. Pape, F. Lehner
Blume, andT.Ahlenstiel, “Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine a, and steroid elimination: 3-year data,” Transplantation, vol. 92, no. 6, pp. 658–662 • 2011

Similar Papers

Loading similar papers…